Advanced Filters
noise

Greenfield, Wisconsin Clinical Trials

A listing of Greenfield, Wisconsin clinical trials actively recruiting patient volunteers.

Found 361 clinical trials
M Matthew Durand, PhD

Passive Limb Movement Study

Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. No studies have examined how femoral blood flow responds to both passive leg movement, a measure of microvascular function, as well as active leg contractions, a measure of the …

18 - 85 years of age All Phase N/A
N Nicole L Lohr, MD PhD

Red Light Treatment in Peripheral Artery Disease

Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (<.9 or >1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition …

18 - 85 years of age All Phase N/A

Study of LYL314 in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

18 years of age All Phase 1/2
R Reza Shaker, MD

External Pharyngeal Exerciser and Pharyngeal Phase of Swallowing

This study of healthy young and elderly individuals is intended to assess the effects of pharyngeal exerciser on pharyngeal pressure phenomenon during swallowing. Our specific aim is to test if the pharyngeal exerciser increases the workload of muscles involved in pharyngeal phase of swallowing.

18 - 85 years of age All Phase N/A
R Reza Shaker, MD

External UES Band (Shaker Pressure Band) and GERD

This protocol is a study to assess the efficacy of an external upper esophageal band to decrease subjective nighttime symptoms related to esophageal reflux into the pharynx.

18 - 85 years of age All Phase N/A
L Lindsay Puckett, MD

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.

18 years of age All Phase 2
K Katie Loffredo, RN,BSN,CCRC

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial …

18 years of age Female Phase 4

Gestational Diabetes and Pharmacotherapy (GAP)

The goal of this study is to compare two different thresholds for initiation of medical treatment for GDM. Pregnant women diagnosed with GDM will be randomized to either start pharmacotherapy when they have reached at least 20% or at least 40% of capillary blood glucose (CBG) values above the target …

18 - 45 years of age Female Phase 4
S Site Public Contact

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such …

18 years of age All Phase 2

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

18 years of age Female Phase 2

Simplify language using AI